These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

53 related articles for article (PubMed ID: 26785228)

  • 21. Colistin in critically ill patients.
    Boisson M; Gregoire N; Couet W; Mimoz O
    Minerva Anestesiol; 2013 Feb; 79(2):200-8. PubMed ID: 23241733
    [TBL] [Abstract][Full Text] [Related]  

  • 22. To B or not to B, that is the question: is it time to replace colistin with polymyxin B?
    Kassamali Z; Danziger L
    Pharmacotherapy; 2015 Jan; 35(1):17-21. PubMed ID: 25346395
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dosing of colistin-back to basic PK/PD.
    Bergen PJ; Li J; Nation RL
    Curr Opin Pharmacol; 2011 Oct; 11(5):464-9. PubMed ID: 21835694
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Optimizing colistin dosing: Is a loading dose necessary?
    Nazer LH; Anabtawi N
    Am J Health Syst Pharm; 2017 Jan; 74(1):e9-e16. PubMed ID: 28007716
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Colistin: understanding and applying recent pharmacokinetic advances.
    Ortwine JK; Kaye KS; Li J; Pogue JM
    Pharmacotherapy; 2015 Jan; 35(1):11-6. PubMed ID: 25187500
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Colistin pharmacokinetics: the fog is lifting.
    Couet W; Grégoire N; Marchand S; Mimoz O
    Clin Microbiol Infect; 2012 Jan; 18(1):30-9. PubMed ID: 21988234
    [TBL] [Abstract][Full Text] [Related]  

  • 27. 'Old' antibiotics for emerging multidrug-resistant bacteria.
    Bergen PJ; Landersdorfer CB; Lee HJ; Li J; Nation RL
    Curr Opin Infect Dis; 2012 Dec; 25(6):626-33. PubMed ID: 23041772
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Colistin: Revival of an Old Polymyxin Antibiotic.
    Dijkmans AC; Wilms EB; Kamerling IM; Birkhoff W; Ortiz-Zacarías NV; van Nieuwkoop C; Verbrugh HA; Touw DJ
    Ther Drug Monit; 2015 Aug; 37(4):419-27. PubMed ID: 25549206
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Use of Colistin in Critically Ill Patients.
    Marchaim D; Kaye D; Kaye KS
    Adv Exp Med Biol; 2019; 1145():155-179. PubMed ID: 31364078
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Multicomponent antibiotic substances produced by fermentation: implications for regulatory authorities, critically ill patients and generics.
    Brink AJ; Richards GA; Colombo G; Bortolotti F; Colombo P; Jehl F
    Int J Antimicrob Agents; 2014 Jan; 43(1):1-6. PubMed ID: 23920094
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Colistin: efficacy and safety in different populations.
    Shahbazi F; Dashti-Khavidaki S
    Expert Rev Clin Pharmacol; 2015; 8(4):423-48. PubMed ID: 26041134
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Multidrug-resistant Gram-negative infections: the use of colistin.
    Michalopoulos AS; Karatza DC
    Expert Rev Anti Infect Ther; 2010 Sep; 8(9):1009-17. PubMed ID: 20818945
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Polymyxin B versus colistin: an update.
    Cai Y; Lee W; Kwa AL
    Expert Rev Anti Infect Ther; 2015; 13(12):1481-97. PubMed ID: 26488563
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Colistin Use in Neonates and Children With Infections Due to Carbapenem-resistant Bacteria.
    Antachopoulos C; Iosifidis E
    Pediatr Infect Dis J; 2017 Sep; 36(9):905-907. PubMed ID: 28650936
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Antibiotics: new and old drugs, rational prescription].
    de With K; Stocker H; Borde J; Kern WV
    Dtsch Med Wochenschr; 2012 Feb; 137(5):186-9. PubMed ID: 22278687
    [No Abstract]   [Full Text] [Related]  

  • 36. Current and future treatment options for infections caused by multidrug-resistant Gram-negative pathogens.
    Poulakou G; Bassetti M; Righi E; Dimopoulos G
    Future Microbiol; 2014; 9(9):1053-69. PubMed ID: 25340835
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Colistin: re-emergence of the 'forgotten' antimicrobial agent.
    Dhariwal AK; Tullu MS
    J Postgrad Med; 2013; 59(3):208-15. PubMed ID: 24029199
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The use of extended-interval aminoglycoside dosing strategies for the treatment of moderate-to-severe infections encountered in critically ill surgical patients.
    Mueller EW; Boucher BA
    Surg Infect (Larchmt); 2009 Dec; 10(6):563-70. PubMed ID: 20035611
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Strategies for the safe use of colistin.
    Ortwine JK; Sutton JD; Kaye KS; Pogue JM
    Expert Rev Anti Infect Ther; 2015; 13(10):1237-47. PubMed ID: 26182825
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Colistin and polymyxin B in critical care.
    Michalopoulos A; Falagas ME
    Crit Care Clin; 2008 Apr; 24(2):377-91, x. PubMed ID: 18361952
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.